肿瘤相关巨噬细胞来源的白细胞介素-23将肾癌谷氨酰胺成瘾与免疫逃逸联系起来
本研究探讨谷氨酰胺代谢是否影响透明细胞肾细胞癌(ccRCC)的局部免疫监视。分析TCGA和上海队列发现,高IL-23表达与较差生存显著相关;机制上,ccRCC肿瘤细胞消耗谷氨酰胺导致微环境谷氨酰胺缺乏,通过HIF1α诱导肿瘤浸润巨噬细胞分泌IL-23,进而促进调节性T细胞增殖并抑制细胞毒性淋巴细胞杀伤。IL-23阻断可延长荷瘤小鼠生存、增强T细胞毒性并提升抗PD-1疗效。
要点
- 高IL-23表达与ccRCC患者总生存和无癌生存较差显著相关。
- 谷氨酰胺缺乏通过HIF1α诱导巨噬细胞分泌IL-23,促进免疫逃逸。
- IL-23阻断可增强抗PD-1疗效,是ccRCC潜在免疫治疗靶点。
核心结论
- 巨噬细胞分泌的IL-23增强谷氨酰胺成瘾肿瘤中的Treg功能,IL-23是ccRCC有前景的免疫治疗靶点。
研究设计与样本
- 分析TCGA队列和上海队列的ccRCC肿瘤数据,并用新鲜人ccRCC肿瘤和小鼠肿瘤细胞进行体内外研究。
主要发现
- TCGA队列中高IL-23表达与总生存(HR=2.04)和无癌生存(HR=2.95)较差显著相关(均p<0.001)。
- 上海队列中高IL-23表达与总生存(HR=2.07)和无癌生存(HR=3.92)较差显著相关(均p<0.001)。
- IL-23阻断延长荷瘤小鼠生存,促进人ccRCC肿瘤体外培养中T细胞毒性,并增强抗PD-1抗体的治疗获益。
- ccRCC肿瘤细胞消耗谷氨酰胺导致细胞外谷氨酰胺局部缺乏,通过激活HIF1α诱导肿瘤浸润巨噬细胞分泌IL-23。
- IL-23激活调节性T细胞增殖并促进IL-10和TGFβ表达,从而抑制细胞毒性淋巴细胞对肿瘤细胞的杀伤。
临床怎么用
- IL-23高表达可作为ccRCC预后不良的潜在生物标志物。
- IL-23阻断单用或联合免疫检查点抑制剂可能成为ccRCC治疗策略。
局限性
- 谷氨酰胺剥夺和IL-23对其他免疫细胞的影响尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glutamine addiction is a hallmark of clear cell renal cell carcinoma (ccRCC); yet whether glutamine metabolism impacts local immune surveillance is unclear. This knowledge may yield novel immunotherapeutic opportunities. OBJECTIVE: To seek a potential therapeutic target in glutamine-addicted ccRCC. DESIGN, SETTING, AND PARTICIPANTS: Tumors from ccRCC patients from a Shanghai cohort and ccRCC tumor data from The Cancer Genome Atlas (TCGA) cohort were analyzed. In vivo and in vitro studies were conducted with fresh human ccRCC tumors and murine tumor cells. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Immune cell numbers and functions were analyzed by flow cytometry. Glutamine and cytokine concentrations were determined. Survival was compared between different subpopulations of patients using Kaplan-Meier and Cox regression analyses. RESULTS AND LIMITATIONS: We found that in ccRCC, high interleukin (IL)-23 expression was significantly associated with poor survival in both TCGA (overall survival [OS] hazard ratio [HR]=2.04, cancer-specific survival [CSS] HR=2.95; all p<0.001) and Shanghai (OS HR=2.07, CSS HR=3.92; all p<0.001) cohorts. IL-23 blockade prolongs the survival of tumor-bearing mice, promotes T-cell cytotoxicity in in vitro cultures of human ccRCC tumors, and augments the therapeutic benefits of anti-PD-1 antibodies. Mechanistically, glutamine consumption by ccRCC tumor cells results in the local deprivation of extracellular glutamine, which induces IL-23 secretion by tumor-infiltrating macrophages via the activation of hypoxia-inducible factor 1α (HIF1α). IL-23 activates regulatory T-cell proliferation and promotes IL-10 and transforming growth factor β expression, thereby suppressing tumor cell killing by cytotoxic lymphocytes. The positive correlations between glutamine metabolism, IL-23 levels, and Treg responses are confirmed in both TCGA cohort and tumors from Shanghai ccRCC patients. Study limitations include the unclear impacts of glutamine deprivation and IL-23 on other immune cells. CONCLUSIONS: Macrophage-secreted IL-23 enhanced Treg functions in glutamine-addicted tumors; thus, IL-23 is a promising target for immunotherapy in ccRCC. PATIENT SUMMARY: In this study, we analyzed the immune components in glutamine-addicted clear cell renal cell carcinoma (ccRCC) tumors from two patient cohorts and conducted both in vitro and in vivo studies. We found that ccRCC tumor cell-intrinsic glutamine metabolism orchestrates immune evasion via interleukin (IL)-23, and IL-23-high patients had significantly poorer survival than IL-23-low patients. IL-23 should thus be considered a therapeutic target in ccRCC, either alone or in combination with immune checkpoint inhibitors.
引用
- Fu Q, Xu L, Wang Y, et al. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Eur Urol. 2018. PMID: 30293904. doi:10.1016/j.eururo.2018.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。